Fax: +39 079 946714
Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma
Article first published online: 12 JUN 2002
Copyright © 2002 American Cancer Society
Volume 94, Issue 12, pages 3157–3168, 15 June 2002
How to Cite
Baldinu, P., Cossu, A., Manca, A., Satta, M. P., Pisano, M., Casula, M., Dessole, S., Pintus, A., Tanda, F. and Palmieri, G. (2002), Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer, 94: 3157–3168. doi: 10.1002/cncr.10606
- Issue published online: 12 JUN 2002
- Article first published online: 12 JUN 2002
- Manuscript Accepted: 7 JAN 2002
- Manuscript Revised: 2 JAN 2002
- Manuscript Received: 31 OCT 2001
- Assessorato alla Programmazione
- Regione Autonoma della Sardegna “Progetto Genetica e Tumori nel Nord-Sardegna,”
- Italian Association for Cancer Research
- endometrial carcinoma;
- polymerase chain reaction;
- microsatellite instability;
- mutational analysis;
Microsatellite instability (MSI) is due mostly to a defective DNA mismatch repair (MMR). Inactivation of the two principal MMR genes, hMLH1 and hMSH2, and the PTEN tumor suppressor gene seems to be involved in endometrial tumorigenesis. In this study, Sardinian patients with endometrial carcinoma (EC) were analyzed to assess the prevalence of both the mutator phenotype (as defined by the presence of MSI and abnormal MMR gene expression at the somatic level) and the hMLH1, hMSH2, and PTEN germline mutations among patients with MSI positive EC.
Paraffin embedded tissue samples from 116 consecutive patients with EC were screened for MSI by polymerase chain reaction-based microsatellite analysis. Immunohistochemistry (IHC) with anti-hMLH1 and anti-hMSH2 antibodies was performed on MSI positive tumor tissue sections. Germline DNA was used for mutational screening by denaturing high-performance liquid chromatography analysis and automated sequencing.
Thirty-nine patients with EC (34%) exhibited MSI; among them, 25 tumor samples (64%) showed negative immunostaining for hMLH1/hMSH2 proteins (referred to as IHC negative). No disease-causing mutation within the coding sequences of the hMLH1/hMSH2 and PTEN genes was found in patients with EC who had the mutator phenotype (MSI positive and IHC negative), except for a newly described hMLH1 missense mutation, Ile655Val, that was observed in 1 of 27 patients (4%). Although MSI was more common among patients with advanced-stage EC and increased as the tumor grade increased, no significant correlation with disease free survival or overall survival was observed among the two groups (MSI positive or MSI negative) of patients with EC.
In patients with MSI positive EC, epigenetic inactivations rather than genetic mutations of the MMR genes seem to be involved in endometrial tumorigenesis. No prognostic value was demonstrated for MSI in patients with EC. Cancer 2002;94:3157–68. © 2002 American Cancer Society.